Lung deposition and protective effect of terbutaline delivered from pressurized metered-dose inhalers and the Turbuhaler in asthmatic individuals.

We investigated the relationship between pulmonary deposition of terbutaline and bronchoprotection against methacholine and histamine with the Turbuhaler (AstraZeneca, Lund, Sweden) and a pressurized metered dose inhaler (pMDI) in 13 asthmatic patients. The study was done with a randomized, double blind, double dummy, and crossover design. On different days, the provocative concentration of histamine causing a 20% decrease in FEV(1) (PC(20) histamine) and PC(20) methacholine were determined before and at 1.5, 3, and 6 h after inhalation of 0.25 or 0.5 mg of terbutaline sulfate. The Turbuhaler delivered significantly more drug than did the pMDI (% of the nominal metered dose and 95% confidence interval): 20.8% (16.4 to 26.6%) and 16.9% (13.2 to 21.7%) versus 4.8% (3.8 to 6.1%) and 7.4% (5.8 to 9.5%), respectively. Average protection against histamine over 6 h was 0.66 (95% CI: 0.45 to 0.87) doubling concentrations (DC) after inhalation of 0.25 mg and 1.08 (95% CI: 0.87 to 1.29) DC after 0.5 mg terbutaline via pMDI, and 1.07 (95% CI: 0.87 to 1.29) DC after 0.25 mg and 1.24 (95% CI: 1.03 to 1.45) DC after 0.50 mg via Turbuhaler. Protection against methacholine was also dose- and device-dependent. The dose needed to obtain the same pulmonary deposition with the pMDI was 3.14 times greater than with the Turbuhaler, and that needed for the same protective effect was 2.1 and 3.2 times greater for histamine and methacholine, respectively. We conclude that pulmonary deposition of terbutaline was predictive of the clinical response.

[1]  S. Newman.  Can lung deposition data act as a surrogate for the clinical response to inhaled asthma drugs? , 2000, British journal of clinical pharmacology.

[2]  B. Laube,et al.  The efficacy of slow versus faster inhalation of cromolyn sodium in protecting against allergen challenge in patients with asthma. , 1998, The Journal of allergy and clinical immunology.

[3]  W. Busse,et al.  Efficacy and safety of inhaled corticosteroids. New developments. , 1998, American journal of respiratory and critical care medicine.

[4]  P. O'Byrne,et al.  Dose-response protective effect of salbutamol on methacholine airway responsiveness using pressurized metered dose inhalers and Turbuhalers. , 1998, Canadian Respiratory Journal.

[5]  R. Pauwels,et al.  Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers. , 1997, The European respiratory journal.

[6]  I. Danta,et al.  Metaproterenol responsiveness after methacholine- and histamine-induced bronchoconstriction. , 1996, Chest.

[7]  R. Pauwels,et al.  The inhalation device influences lung deposition and bronchodilating effect of terbutaline. , 1996, American journal of respiratory and critical care medicine.

[8]  T. W. van der Mark,et al.  Home assessment of peak inspiratory flow through the Turbohaler in asthmatic patients. , 1996, Thorax.

[9]  D. Rogers,et al.  Determining equivalence of inhaled medications. Consensus statement from a workshop of the British Association for Lung Research, held at Royal Brompton National Heart & Lung Institute, London 24 June 1994. , 1995, Respiratory medicine.

[10]  T. O'riordan,et al.  Changing patterns of aerosol deposition during methacholine bronchoprovocation. , 1993, Chest.

[11]  S. Anderson,et al.  Airway responsiveness : standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults , 1993 .

[12]  A. Dirksen,et al.  Airway calibre as a confounder in interpreting bronchial responsiveness in asthma. , 1992, Thorax.

[13]  R. Pauwels,et al.  The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours. , 1992, The Journal of allergy and clinical immunology.

[14]  S. Holgate,et al.  A longitudinal study of baseline FEV1 and bronchial responsiveness in patients with asthma. , 1992, The European respiratory journal.

[15]  P. O'Byrne,et al.  Tachyphylaxis to inhaled methacholine in normal but not asthmatic subjects. , 1990, Journal of applied physiology.

[16]  S. Spiro,et al.  Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution. , 1990, Thorax.

[17]  E. Corey,et al.  Localization of the site of the bronchoconstrictor effects of leukotriene C4 compared with that of histamine in asthmatic subjects. , 1989, The American review of respiratory disease.

[18]  K. Svensson,et al.  Comparative pharmacokinetics of unlabeled and deuterium-labeled terbutaline: demonstration of a small isotope effect. , 1988, Journal of pharmaceutical sciences.

[19]  B. Lipworth,et al.  Beta-adrenoceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma. , 1988, British journal of clinical pharmacology.

[20]  Serial distribution of bronchoconstriction in normal subjects. Methacholine versus histamine. , 1988, The American review of respiratory disease.

[21]  N. D. Wong,et al.  Tolerance to methacholine inhalation challenge in nonasthmatic subjects. , 1988, The American review of respiratory disease.

[22]  A. Tattersfield,et al.  Dose related effects of salbutamol and ipratropium bromide on airway calibre and reactivity in subjects with asthma. , 1988, Thorax.

[23]  P. O'Byrne,et al.  Tachyphylaxis to inhaled histamine in asthmatic subjects. , 1987, Journal of applied physiology.

[24]  M. Kaliner,et al.  Histamine and asthma. , 1987, The American review of respiratory disease.

[25]  R. Ahrens,et al.  A method for comparing the peak intensity and duration of action of aerosolized bronchodilators using bronchoprovocation with methacholine. , 2015, The American review of respiratory disease.

[26]  Cockcroft Dw,et al.  Measurement of responsiveness to inhaled histamine: comparison of FEV1 and SGaw. , 1983, Annals of allergy.

[27]  P. Barnes,et al.  Dose-response curves to inhaled beta-adrenoceptor agonists in normal and asthmatic subjects. , 1983, British journal of clinical pharmacology.

[28]  P. Barnes,et al.  Autoradiographic localization of autonomic receptors in airway smooth muscle. Marked differences between large and small airways. , 1983, The American review of respiratory disease.

[29]  J. Malo,et al.  Time course of the bronchoconstriction induced by inhaled histamine and methacholine. , 1983, Journal of applied physiology: respiratory, environmental and exercise physiology.

[30]  P. L. Smith,et al.  A comparison of histamine, methacholine, and exercise airway reactivity in normal and asthmatic subjects. , 1982, The American review of respiratory disease.

[31]  N. Thomson,et al.  Bronchial responsiveness to histamine or methacholine in asthma: measurement and clinical significance. , 1981, The Journal of allergy and clinical immunology.

[32]  E. Juniper,et al.  Airway responsiveness to histamine and methacholine: relationship to minimum treatment to control symptoms of asthma. , 1981, Thorax.

[33]  R. Roberts,et al.  The effect of ipratropium and fenoterol on methacholine-histamine-induced bronchoconstriction. , 1981, British journal of diseases of the chest.

[34]  P. Frith,et al.  Reproducibility and comparison of responses to inhaled histamine and methacholine. , 1978, Thorax.

[35]  F. Hargreave,et al.  Bronchial reactivity to inhaled histamine: a method and clinical survey , 1977, Clinical allergy.